Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TolDCfoRA in Rheumatoid Arthritis
NCT03337165Phase 1Completed
- Sponsor
- Russian Academy of Sciences
- Start
- Dec 2016
- Primary completion
- May 2019
- Modality
- Whole Cell Cancer Vaccines, Dendritic Cell Vaccines
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of autologous tolerogenic dendritic cells in rheumatoid arthritis (RA), sponsored by Russian Academy of Sciences. Primary endpoint: Number of Participants experiencing AEs and SAEs at 6 months. Started Dec 2016; status: completed.
02
Drugs
autologous tolerogenic dendritic cells
03
Conditions
rheumatoid arthritis (RA)
Beyond the preview
Go deeper on NCT03337165.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03337165.